Torque Bio Information

Torque Bio is a biotechnology company developing next generation genetic medicines for serious kidney diseases, with an initial focus on autosomal dominant polycystic kidney disease (ADPKD). Our approach is built around a deeply integrated platform that combines: • Proprietary kidney optimized AAV vectors • Innovative gene replacement and AAV:circular RNA (circRNA) modalities • Targeted, local delivery to the kidney Together, these capabilities are designed to enable durable, precise therapies that address disease biology at its source, rather than treating downstream symptoms. Torque Bio is advancing therapeutic programs for both major genetic drivers of ADPKD and is also building a versatile AAV:circRNA platform with potential applications beyond kidney disease. Our circRNA technology enables sustained, endogenous expression of tailored circRNA cargos, unlocking new therapeutic mechanisms from a single administration. Based in Durham, North Carolina, Torque Bio is led by an experienced team with deep expertise across gene therapy discovery, manufacturing, and clinical translation. We are united by a shared mission: to deliver meaningful, long term impact for patients with serious genetic diseases.